“DOCTOR FILES: When the Unknown Is Not So Bad” – Los Angeles Times
Here is a figure reproduced in Fortune, showing that when researchers publish articles raising questions about the harms of salt, they cite other researchers who raised similar questions. By contrast, when they definitively argue in favor of the harms, they cite other definitive colleagues. Some of this makes scientific sense. If you show a particular…
I am currently on sabbatical (and enjoying some hiking in the Appalachian Mountains). Blog posts will resume in September!
I recently spoke with a reporter about a new effort, by Medicare, to persuade dialysis centers to care for a wider range of primary care health needs for people with kidney failure. I’ll give you a teaser for that article below, but first want to point out what struck me as the most notable part…
The Duke Alumni Magazine just published a Q & A about my new book, Sick to Debt. Here was the picture accompanying that article. Y’all agree that this should have been the “author photo” on the back cover? Link to the Q & A
My article with Peter Bach of Memorial Sloan Kettering continues to generate debate. The two of us argues that copay assistance programs from pharmaceutical companies help specific patients in the short run, but make it easier for drug companies to demand high prices for their products. Here is one take on the topic, spurred on…
The oncologist had prescribed Xgeva hoping it would strengthen her bones while also delaying the progression of Angela Kahn’s breast cancer. But Kahn (a pseudonym) couldn’t get over the price of the drug. Before the oncologist had a chance to ask how she was feeling, she blurted out that the medication cost “$15,000 a shot.”…